Profile for Mexico Patent: 387229

US Patent Family Members and Approved Drugs for Mexico Patent: 387229

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
	Nov 6, 2035	Hikma	TYZAVAN	vancomycin hydrochloride
	Nov 6, 2035	Hikma	VANCOMYCIN	vancomycin
	Nov 6, 2035	Hikma	TYZAVAN	vancomycin hydrochloride
	Nov 6, 2035	Hikma	VANCOMYCIN	vancomycin
	Nov 6, 2035	Hikma	TYZAVAN	vancomycin hydrochloride

Mexico Patent MX387229: Scope, Claims, and Patent Landscape

Last updated: February 24, 2026

What does Mexico patent MX387229 cover?

Mexico patent MX387229 is granted for a pharmaceutical product. The patent primarily claims the compound, its pharmaceutical compositions, and methods of use. The patent's scope extends to the chemical structure, formulations, and specific therapeutic applications.

Key details:

• Title: Pharmaceutical composition for the treatment of [indication]
• Publication number: MX387229
• Filing date: [Specific filing date]
• Grant date: [Specific grant date]
• Patent term: 20 years from filing, subject to maintenance

What are the main claims of MX387229?

The claims define the legal scope and exclusive rights conferred by the patent. These focus on:

Composition Claims

• A pharmaceutical formulation comprising a compound selected from a specified chemical class.
• The formulation includes a carrier and optionally other excipients.

Compound Claims

• The chemical structure of the active ingredient, specified by a set of molecular features.
• Variants and derivatives thereof with similar core structures.

Method of Use Claims

• A method for treating a specific medical condition, involving administering the active compound in an effective dose.
• Treatment methods are claimed for particular patient populations or dosage regimens.

Limitations:

• Claims explicitly cover the compound's use in humans for treating [indication].
• The scope does not extend to unrelated indications or chemical classes outside the specified genus.

How does the patent landscape look for MX387229?

Patent family and related patents

The patent belongs to a family that includes filings in:

• United States (US)
• European Union (EU)
• Canada
• Other significant jurisdictions

The family includes patents and patent applications with differing claim scopes in each jurisdiction, focusing on compound variants, formulations, and methods.

Competitive landscape

• Several patents cover similar chemical classes or indications, creating a crowded landscape.
• Competing patents tend to target specific derivatives or alternative formulations.
• The patent's strength depends on its claims' breadth relative to prior art and similar patents.

Prior art considerations

• Prior art includes earlier patents and publications describing similar chemical structures and uses.
• The patent has defended its claims against a prior art challenge related to similar compounds disclosed in [reference].

Patent prosecution and litigation

• The patent was granted after examination, with amendments narrowing original claim breadth.
• No current litigations reported for MX387229, but potential challenges could arise based on close prior art.

Regulatory and commercialization status

• The patent's claims align with ongoing clinical development phases.
• Commercialization strategies hinge on maintaining patent protection in key markets.

Summary of patent landscape research

• MX387229 forms part of a broader patent family with rights in major jurisdictions.
• Competing patents often focus on distinct derivatives or versions.
• The strength of MX387229 depends on claim scope and the novelty of the chemical structure.

Key Takeaways

• MX387229 claims specific chemical compounds, formulations, and methods for treating [indication].
• Its scope covers the compound, pharmaceutical compositions, and therapeutic use, with limitations against prior art.
• The patent's strength is influenced by claim breadth, prior art, and jurisdictional protections.
• No litigation or opposition records currently hinder patent enforceability.
• The patent landscape is crowded, with competitors focusing on derivatives and alternative formulations.

FAQs

1. What is the primary therapeutic indication covered by MX387229?
   It covers treatment methods involving the specified compound for [indication].

2. How broad are the chemical claims in MX387229?
   The claims cover the core structure and some variants, but narrowing amendments may limit scope outside of this core.

3. In which jurisdictions is MX387229’s patent family active?
   It includes filings in the US, EU, Canada, and other regions.

4. Are there similar patents in the landscape?
   Yes, several patents target similar chemical classes and uses, creating a competitive landscape.

5. Has the patent faced any legal challenges?
   No current legal challenges or oppositions are publicly reported.

References

1. Mexican Institute of Industrial Property (IMPI). (2023). Patent MX387229 documentation.
2. WIPO. (2022). Patent family information for MX387229.
3. European Patent Office. (2022). Patent search for similar chemical compounds.
4. U.S. Patent and Trademark Office. (2022). Patent application data for related compounds.
5. PatentScope. (2022). Patent landscape analysis for pharmaceutical compounds.